Contents

Search

delgocitinib (Anzupgo)

Indications: - moderate to severe chronic hand eczema in adults (FDA-approved) Dosage: cream Adverse effects: - majority of adverse events were nonserious, mild or moderate & not related to treatment Clinical trials: - phase 3 trial

Interactions

drug adverse effects of tyrosine kinase inhibitor(s)

General

Janus kinase inhibitor; JAK inhibitor topical agent

Database Correlations

PUBCHEM cid=50914062

References

  1. Klimanskis C Positive phase 3 results reported for delgocitinib cream for chronic hand eczema. Healio. Dec 16, 2022 https://www.healio.com/news/dermatology/20221216/positive-phase-3-results-reported-for-delgocitinib-cream-for-chronic-hand-eczema - ClinicalTrials.gov Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). https://clinicaltrials.gov/ct2/show/NCT04871711.